Co-administration of TGFβ-blocking and anti-PD-L1 antibodies reduced TGFβ signaling in stromal cells, facilitated T-cell penetration into the center of the tumor, and activated antitumor immunity and tumor regression. This evidence concerns the gene TGFB1 and neoplasm.